Passage Bio, Inc. Elects Derrell Porter as Class I Director and Member of its Audit Committee
May 28, 2021 at 09:01 pm
Share
Passage Bio, Inc. at its Annual Meeting of Stockholders held on May 27, 2021, elected Derrell Porter, M.D. to serve a three-year term, which will expire at the 2024 annual meeting of stockholders. The company also announced the election of Derrell D. Porter, M.D., to its Audit Committee, effective as of May 27, 2021, the date of Passage Bio’s Annual Meeting of Stockholders. Dr. Porter is founder and chief executive officer of Cellevolve Bio. Prior to founding and leading Cellevolve Bio in 2020, Dr. Porter served as senior vice president and head of Commercial at Atara Biotherapeutics, Inc. from May 2017 to October 2019.
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimerâs disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
PASSAGE BIO, INC. 
